Cyclin e-mediated human proopiomelanocortin regulation as a therapeutic target for cushing disease

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages 2557-2564

  Liu, Ning Ai ^a   Araki, Takako ^a   Cuevas Ramos, Daniel ^a   Hong, Jiang ^a   Ben Shlomo, Anat ^a   Tone, Yukiko ^a   Tone, Masahide ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; CORTICOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; GLUCOCORTICOID RECEPTOR; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR 1B; NUCLEAR RECEPTOR NUR77; PITUITARY RESTRICTED TRANSCRIPTION FACTOR; PROOPIOMELANOCORTIN; ROSCOVITINE; SMALL INTERFERING RNA; T BOX TRANSCRIPTION FACTOR 19; TESTICULAR ORPHAN NUCLEAR RECEPTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR PITX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PURINE DERIVATIVE;

ACTH SECRETING ADENOMA; ADOLESCENT; ADULT; AGED; ANIMAL CELL; ARTICLE; ATT20 CELL; BINDING AFFINITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CUSHING DISEASE; DISEASE DURATION; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUCIFERASE ASSAY; MALE; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; PITUITARY TUMOR CELL LINE; POMC GENE; PRIORITY JOURNAL; PROMOTER REGION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TBX19 GENE; TPIT GENE; WESTERN BLOTTING; YOUNG ADULT; ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PITUITARY ACTH HYPERSECRETION; PRIMARY CELL CULTURE; PROCEDURES; TUMOR CELL CULTURE;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYCLIN E; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PITUITARY ACTH HYPERSECRETION; PRIMARY CELL CULTURE; PRO-OPIOMELANOCORTIN; PURINES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84953878111     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1606     Document Type: Article

References (44)

1. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374-381.
2. Stewart PM, Krone, NP. Classification and pathophysiology of Cushing's syndrome. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook of Endocrinology. 12th ed. Philadelphia: Elsevier; 2012:500-515.
3. Raverot G, Wierinckx A, Jouanneau E, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010;163:35-43.
4. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92:976-981.
5. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96:632-642.
6. Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004;89:6348-6357.
7. Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab. 2012;97:1194-1201.
8. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol. 2011;7:279-289.
9. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462.
10. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
11. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366: 914-924.
12. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
13. Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med. 2005; 352:2457-2458.
14. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257-266.
15. Treier M, Rosenfeld MG. The hypothalamic-pituitary axis: co-development of two organs. Curr Opin Cell Biol. 1996;8:833-843.
16. Lamolet B, Pulichino AM, Lamonerie T, et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001;104:849-859.
17. Liu J, Lin C, Gleiberman A, et al. Tbx19, a tissue-selective regulator ofPOMCgene expression. Proc Natl Acad SciUSA. 2001;98:8674-8679.
18. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev. 2006;20:2871-2886.
19. Du L, Bergsneider M, Mirsadraei L, et al. Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease. Proc Natl Acad Sci USA. 2013;110:8555-8560.
20. Lugo DI, Pintar JE. Ontogeny of basal and regulated secretion from POMCcells of the developing anterior lobe of the rat pituitary gland. Dev Biol. 1996;173:95-109.
21. Labrie F, Veilleux R, Lefevre G,CoyDH,Sueiras-Diaz J, Schally AV. Corticotropin-releasing factor stimulates accumulation of adenosine 3-, 5-monophosphate in rat pituitary corticotrophs. Science. 1982;216:1007-1008.
22. Maira M, Martens C, Batsche E, Gauthier Y, Drouin J. Dimerspecific potentiation of NGFI-B (Nur77) transcriptional activity by the protein kinase A pathway and AF-1-dependent coactivator recruitment. Mol Cell Biol. 2003;23:763-776.
23. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C. NF-B participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem. 2004;279:10837-10840.
24. Sherr CJ, Roberts JM. Living with or without cyclins and cyclindependent kinases. Genes Dev. 2004;18:2699-2711.
25. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992;70:993-1006.
26. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell. 1991;65:1053-1061.
27. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997; 3:222-225.
28. Loeb KR, Kostner H, Firpo E, et al. A mouse model for cyclin Edependent genetic instability and tumorigenesis. Cancer Cell. 2005; 8:35-47.
29. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 2011;71:3377-3386.
30. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin Dand cyclinEexpression in normal and adenomatous pituitary. Eur J Endocrinol. 2000;143:R1-R6.
31. Roussel-Gervais A, Bilodeau S, Vallette S, et al. Cooperation between Cyclin E and p27(Kip1) in pituitary tumorigenesis. Mol Endocrinol. 2010;24:1835-1845.
32. Liu NA, Jiang H, Ben-Shlomo A, et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA. 2011;108:8414-8419.
33. Zhou C, Wawrowsky K, Bannykh S, Gutman S, Melmed S. E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol. 2009;23:2000-2012.
34. Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011;121:4712-4721.
35. Langlais D, Couture C, Sylvain-Drolet G, Drouin J. A pituitaryspecific enhancer of the POMC gene with preferential activity in corticotrope cells. Mol Endocrinol. 2011;25:348-359.
36. Bumaschny VF, de Souza FS, Lopez Leal RA, et al. Transcriptional regulation of pituitary POMC is conserved at the vertebrate extremes despite great promoter sequence divergence. Mol Endocrinol. 2007;21:2738-2749.
37. Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y, Drouin J. Tpit determines alternate fates during pituitary cell differentiation. Genes Dev. 2003;17:738-747.
38. PulichinoAM,Vallette-Kasic S, Couture C, et al. Humanand mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes Dev. 2003;17:711-716.
39. Couture C, Saveanu A, Barlier A, et al. Phenotypic homogeneity and genotypic variability in a large series of congenital isolated ACTHdeficiency patients with TPIT gene mutations. J Clin Endocrinol Metab. 2012;97:E486-E495.
40. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 2007;96:29-37.
41. Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer. 2010; 46:3243-3250.
42. Lamberts SW. Glucocorticoid receptors and Cushing's disease. Mol Cell Endocrinol. 2002;197:69-72.
43. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86:117-123.
44. Kino T, Ichijo T, Amin ND, et al. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol. 2007;21:1552-1568.